acamprosate vs methylphenidate
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and methylphenidate. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Ritalin, Concerta
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Methylphenidate extended-release capsules are a stimulant medicine. They are used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6 to 12.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
This medicine treats Attention Deficit Hyperactivity Disorder (ADHD) in children. ADHD can make it hard to focus, pay attention, and control impulsive behavior. This medicine can help improve focus and reduce hyperactivity.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Methylphenidate is a central nervous system (CNS) stimulant. It works by affecting chemicals in the brain that contribute to hyperactivity and impulsivity. The extended-release capsules release the medicine in two stages, providing both an immediate and a delayed effect.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Headache
- • Trouble sleeping (insomnia)
- • Upper abdominal pain
- • Decreased appetite
- • Loss of appetite (anorexia)
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Product Quality Issue 5,241
- Drug Administration Error 1,901
- Wrong Technique In Drug Usage Process 1,772
- Application Site Erythema 1,684
- Drug Dose Omission 1,478
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
This medicine has a high potential for abuse and dependence. Your doctor will assess your risk before prescribing it and monitor you during treatment. Misuse of this medicine may cause sudden death or serious heart problems.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm your unborn baby. There is a pregnancy registry for women who take ADHD medicines during pregnancy.
Also Compare, Nearby Drugs
Compare methylphenidate with
How to Read This acamprosate vs methylphenidate Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while methylphenidate sits within the CNS Stimulant class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while methylphenidate has 12,076. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or methylphenidate.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.